CRH and Alzheimer disease: However, the situation is more complicated if we consider the effects of newly developed putative ADs: indeed, whereas the effects of a CNR1 ligand are abolished by suppression of neurogenesis (Jiang et al., 2005) as observed with monoaminergic-acting compounds, most of the AD-like effects of MCHR1 (Melanin-concentrating hormone receptor 1), CRH1 (corticotrophin-releasing hormone), or V1b (Vasopressin V1b) antagonists are not prevented by ablation of neurogenesis (David et al., 2007; Surget et al., 2008).